Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04039243 · ClinicalTrials.gov registry record · NA
Addressing Anxiety in 2-3-Year-Olds: A Pilot Intervention Study
A NA study of Fear and Anxiety Disorder of Childhood, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT04039243: Active NA study of Fear and Anxiety Disorder of Childhood, sponsored by Massachusetts General Hospital.
NCT04039243 is a NA study of Fear and Anxiety Disorder of Childhood that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 90 participants, below the 256-participant average among 8 other Fear trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04039243, a NA study of Fear and Anxiety Disorder of Childhood, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the feasibility and efficacy of intervening with 2-year-old children with elevated temperamental Fear and/or Shyness or 3-year-old children with elevated anxiety and their parents, using a parent-child Cognitive Behavioral Therapy (CBT) protocol to reduce anxiety disorders and maintain reduced anxiety at one-year follow-up. Before the COVID-19 pandemic, study visits and treatment sessions were conducted in office. Now all visits and treatment sessions are conducted remotely.
Primary Outcome
The CGI-I is a 7-point scale from 1 (Very Much Improved) to 7 (Very Much Worse). It will be rated by a clinician interviewer blind to treatment condition
Conditions Studied
Interventions
- BEHAVIORAL Being Brave
- OTHER Parent Education
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2019-09-27 |
| Est. Completion | 2026-06-01 |
| Phase | NA |
What the registry record for NCT04039243 still lists
NCT04039243 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 256-participant average among 8 other Fear trials with a reported enrollment target (65% lower).
The record links to 3 conditions, with Fear appearing as the primary indexed condition, and to 2 interventions - of which Being Brave is the first listed.
NCT04039243 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04039243 about?
NCT04039243 is a clinical study titled "Addressing Anxiety in 2-3-Year-Olds: A Pilot Intervention Study". The purpose of this study is to test the feasibility and efficacy of intervening with 2-year-old children with elevated temperamental Fear and/or Shyness or 3-year-old children with elevated anxiety and their parents, using a parent-child Cognitive Behavioral Therapy (CBT) protocol to reduce anxiety...
What is the current status of trial NCT04039243?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2019-09-27. Estimated completion is 2026-06-01.
What conditions does trial NCT04039243 study?
This clinical trial studies the following conditions: Fear, Anxiety Disorder of Childhood, Shyness.
What interventions are being tested in trial NCT04039243?
The interventions under investigation include: Being Brave (BEHAVIORAL), Parent Education (OTHER).
Who is sponsoring clinical trial NCT04039243?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04039243 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fear
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04039243's enrollment target sits among peer trials
90 7th of 8 higher than 2 of 8 other Fear trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fear trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Social Support and Reduced Fear Acquisition
RECRUITING · NA
-
Social Support and Enhanced Fear Extinction
RECRUITING · NA
-
Intracranial Neurophysiological Signatures of Fear and Anxiety in Humans
RECRUITING · NA
-
Effect of rTMS on Anxiety
COMPLETED · NA
-
Does Increasing Attentional Control Decrease Acute Fear Response
COMPLETED · NA
-
Social Activity, Loneliness and Stigma During COVID-19 Outbreak
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI